UNSPSC 51451806: Albendazole sulfone

This classification denotes an antihelminthic agent with the molecular formula C12H15N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UIC88380G, chemically known as methyl n-(5-(propane-1-sulfonyl)-1h-1,3-benzodiazol-2-yl)carbamate, but more generally known as albendazole sulfone, which bears US NIH Compound Identifier 53174. European Medicines Agency schedules albendazole sulfone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05295MIG.

Most nations, for tariff purposes, schedule albendazole sulfone under HS 29339990. SMILES: CCCS(=O)(=O)C1CCC2C(C1)NC([NH]2)NC(=O)OC.

UNSPSC 51451806 Albendazole sulfone is a Commodity code that nominally identifies a specific pharmaceutical compound, but recent state and local solicitations tagged with this code reveal a significant mismatch: the posted opportunities involve procurement of naloxone, first-aid medical supplies, and multi-source generic pharmaceuticals and OTC products—none of which involve albendazole sulfone or antiparasitic medications. The code shows little relevant recent activity aligned with its nominal scope. State and local governments using this code appear to be buying broad pharmaceutical and medical supply categories rather than the specific active pharmaceutical ingredient the code nominally describes, suggesting either cataloging inconsistency or administrative repurposing of the taxonomy entry for general pharmaceutical and medical consumables procurement.

The three identifiable opportunities span diverse issuing bodies: Seminole County, Florida (an IFB for naloxone and drug deactivation systems with a July 26, 2023 response date); the City of Tampa (an ITB for fire department rescue medical and first-aid supplies, estimated at $700,000, with a March 13, 2026 deadline and a 5% SLBE bid discount up to $10,000); the Minnesota Multistate Cooperative Purchasing Alliance administered by the Minnesota Department of Administration (an RFP for generic multi-source pharmaceuticals and OTC products across multiple state and local participants including Oregon, due March 26, 2026); and the Texas Health and Human Services Commission (an RFI posted April 3, 2026, exploring direct-to-manufacturer prescription programs). Geographic activity centers on Florida, Minnesota, Texas, and Oregon, with cooperative purchasing mechanisms extending reach across state lines. The disconnect between the code's pharmaceutical designation and the actual medical-supply and naloxone procurement it tags suggests this code may not reliably identify opportunities in the albendazole sulfone category.